Lake Street analyst Frank Takkinen reiterated a Buy rating on Apyx Medical (APYX – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $4.21.
Takkinen covers the Healthcare sector, focusing on stocks such as NeuroPace, Apyx Medical, and ClearPoint Neuro. According to TipRanks, Takkinen has an average return of -7.4% and a 31.82% success rate on recommended stocks.
Currently, the analyst consensus on Apyx Medical is a Strong Buy with an average price target of $7.88, which is an 87.40% upside from current levels. In a report released today, Craig-Hallum also maintained a Buy rating on the stock with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $9.84 and a one-year low of $1.31. Currently, Apyx Medical has an average volume of 355.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apyx Medical Corp. operates as an energy-based medical technology company. It engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
Read More on APYX:
